Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 7/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | CTSC | P53634 | 3/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5500283 | 0.85 | CTSC (0.51) | CHEK2CHEK1CTSCAURKACTSL | |
| SCHEMBL5499926 | 0.83 | POLB (0.51) | CHEK2CTSCAURKACTSLIKBKE | |
| SCHEMBL5502963 | 0.81 | CTSC (0.59) | CTSCCTSLSYKIKBKBIKBKE | |
| SCHEMBL5496551 | 0.81 | CTSC (0.44) | CTSCAURKACTSLSYKIKBKB | |
| SCHEMBL5501205 | 0.81 | CTSC (0.62) | CTSCCSNK2A1JAK2CTSLJAK3 | |
| SCHEMBL5496471 | 0.79 | CTSC (0.49) | CHEK2CHEK1CTSCCTSLIKBKB | |
| SCHEMBL5513122 | 0.77 | CTSC (0.52) | CHEK2CHEK1CTSCCTSLIKBKB | |
| SCHEMBL5495515 | 0.76 | CTSC (0.39) | CHEK2CHEK1CTSCCSNK2A1CTSL | |
| SCHEMBL30898463 | 0.76 | CHEK2 (0.76) | CHEK2CHEK1IKBKB | |
| SCHEMBL5495448 | 0.75 | RHOA (0.53) | CHEK2CTSCCSNK2A1AURKACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293484-A1 | Thiophene Heteroaryl Amines | SUGEN, INC. | 2007-12-20 | — | — | US | disclosed |
| EP-1753750-A1 | THIOPHENE HETEROARYL AMINES | Sugen, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005113548-A1 | THIOPHENE HETEROARYL AMINES | SUGEN, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293484-A1 | Thiophene Heteroaryl Amines | TTK, CHEK2, ABL1 | CHEK2 2/4885CHEK1 6/4885CTSC 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.